« Return to News | Drug Sponsors

Forest Labs and Nabriva to develop novel antibacterial agent

Friday, June 1, 2012 10:43 AM

Forest Laboratories, an international pharmaceutical manufacturer and marketer, and biotech Nabriva Therapeutics have entered into an agreement for the development of Nabriva’s novel antibacterial agent, BC-3781.

Forest will provide Nabriva with $25 million, and fund and conduct in collaboration with Nabriva certain development activities related to BC-3781 over the next 12 months. BC-3781 belongs to a novel class of antibiotics, the pleuromutilins. BC-3781 exhibits microbiological activity against a wide range of Gram-positive pathogens (including Methicillin-Resistant Staphylococcus aureus or MRSA and penicillin-resistant Streptococcus pneumoniae), as well as certain Gram-negative organisms (including Legionella pneumophila and Chlamydophila pneumoniae), often implicated in respiratory infections.

During the 12-month period, Forest also has the exclusive right to acquire Nabriva. Forest's decision to acquire Nabriva will be dependent upon certain contingencies. No further financial or other terms were disclosed. The transaction is subject to customary regulatory clearances including termination of the applicable Hart-Scott-Rodino waiting period.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.